NRIX Nurix Therapeutics Inc
Company Analysis
Latest News
🟢 Nurix Therapeutics is trading 4.36% up on October 14, 2026, after Roche collaboration drove Q3 revenue
Nurix Therapeutics is trading at $23.09, up 4.36%, following its October 13 report, which showed $673.1 million in revenue, largely from Roche collaboration...
Nurix Posts a $550 Million Profit on Roche's Dime — But Can a One-Time Windfall Justify a $2.5 Billion Valuation?
Shares of Nurix Therapeutics surged 8.5% to $24.00 after the clinical-stage biotech reported third-quarter results that flipped its income statement from deep...
🟢 Nurix Therapeutics is trading 8.45% up in pre-market after reporting $673.1 million in Q3 revenue
Nurix Therapeutics is trading at $24.00, up 8.45% in pre-market after third-quarter results reported October 13. - Revenue was $673.1 million, including...
Nurix Therapeutics third quarter 2026 revenue surges to $673M on $700M Roche collaboration
Nurix Therapeutics reported a massive increase in revenue and a swing to profitability for the third quarter 2026, primarily driven by the closing of its...
🟢 Nurix Therapeutics is trading 4.1% up in after-hours trading after reporting $673.1 million in Q3 revenue
Nurix Therapeutics is trading 4.1% up at $23.07 in after-hours trading following its October 12, 2026, third-quarter results and corporate update. - Revenue...
🟢 Nurix Therapeutics rises 4.1% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Nurix Therapeutics is trading 4.69% down today amid biotech-sector weakness
Nurix Therapeutics is trading at $21.66, down 4.69%, amid biotech-sector weakness; the XBI is down 2.04% during the regular session. - No specific sector...
Nurix Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on October 08, 2026
Wall Street expects Nurix Therapeutics to report a Q3 2026 loss of $0.60 per share on revenue of $24.35 million, as the stock currently trades near $22.88...
🔴 Nurix Therapeutics is trading 6.3% down in pre-market as the cause remains unclear
Nurix Therapeutics is trading at $21.55, down 6.26%, with no verified overnight company announcement directly explaining the pre-market decline. - Search...
Nurix Attracts $20.43 Million Bank of America Stake
In a new 13F filing with the Securities & Exchange Commission, Bank of America Corp DE disclosed that it acquired a new stake in Nurix Therapeutics, Inc....
🔴 Nurix Therapeutics is trading 4.03% down today as Nasdaq and S&P 500 fall
Nurix Therapeutics is trading at $24.64, down 4.03%, as broader equity sentiment weakens. - On September 23, 2026, the Nasdaq Composite is down 0.78% and the...
🟢 Nurix Therapeutics rises 4.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Nurix Therapeutics falls 4.1% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Nurix Therapeutics is trading 4% up today, possibly tied to investor positioning ahead of a fireside chat
Nurix Therapeutics is trading 4.02% up at $26.11, possibly tied to investor positioning ahead of a fireside chat. - It outperformed a weaker broader market on...
🔴 Nurix Therapeutics is trading 4.76% down in pre-market as escalating U.S.-Iran tensions drive risk-off pressure
Nurix Therapeutics is trading 4.76% down at $25.01 after a broad risk-off session tied to escalating U.S.-Iran tensions, oil above $100 per barrel, and weaker...
Nurix Therapeutics downgraded to sell, following wide revenue and earnings miss
Wall Street Zen downgraded Nurix Therapeutics (NRIX) from hold to sell on September 5, 2026. The rating change follows a quarterly earnings report that missed...
🟢 Nurix Therapeutics rises 4.0% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Nurix Therapeutics rises 4.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Nurix Therapeutics Gains T. Rowe Price as Investor via 5.3% Stake
T. Rowe Price Associates disclosed a 5.3% stake in Nurix Therapeutics (NRIX). The investment was revealed in a Schedule 13G filing dated August 14, 2026. The...
Nurix Hits 52-Week High, RBC Raises Price Target to $36
Nurix Therapeutics shares reached a new 52-week high on Tuesday. Royal Bank of Canada increased its price target for the stock to $36 from $33. The firm...